Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”
Complete the form below to unlock access to ALL audio articles.
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of Alderley Park-based ApconiX will tell this month’s conference, Accelerating Cancer Drug Development – from target to patients, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
He said: “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues relegated to secondary importance. However, an improved safety profile is not only an important way to reduce the high rate of drug failure, it can also expedite clinical trials and, above all, it’s the best thing to do for patients.
“With most cancer drugs, patients have to put up with a wide range of adverse effects in return for promised benefits. But that shouldn’t mean patients having to tolerate side effects that could potentially be designed out in the research stage when companies are choosing between candidate chemicals.”
Dr Knight will outline his views as part of the Accelerating Cancer Drug Development conference at Alderley Park on 27 February. Currently more than 50% of ApconiX’s non-clinical safety work is involved with oncology drug development.
“Eliminating pre-clinical safety signals makes everything else easier, from patient recruitment to speed and overall cost. It’s a positive attribute and companies should be taking every opportunity to advance the compound with the best overall profile.
“There is a widespread misunderstanding about what pre-clinical safety is there to do. Many see it largely as a box-ticking exercise but it can be of real value in moving new agents rapidly through clinical trials.”
This article has been republished from materials provided by ApconiX. Note: material may have been edited for length and content. For further information, please contact the cited source.